Physician Assistant Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Theodora Squire

Glen Allen, VA Physician Assistant

NPI 1417591660 CMS profile 11311496

2151 Old Brick Rd, Glen Allen, VA 23060

Open in the dashboard

General payments

$11,172

552 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Theodora Squire of Glen Allen, VA is reported in the CMS Open Payments database as having received $11,172 across 552 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,904 180
2024 General $2,781 145
2023 General $2,128 118
2022 General $2,359 109

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Theodora Squire
  • Virginia median
  • Middle half of Virginia
  • National median

In program year 2025, general payments to Theodora Squire were reported at $3,904. Among 24,845 Virginia profiles paid that year, the median was $179 and the middle half received between $56 and $613.

Show as a table
Year Theodora Squire Virginia median Middle half National median
2019 $0 $162 $50–$582 $163
2020 $0 $111 $36–$367 $114
2021 $0 $125 $37–$450 $132
2022 $2,359 $149 $45–$527 $149
2023 $2,128 $161 $50–$554 $160
2024 $2,781 $171 $55–$585 $164
2025 $3,904 $179 $56–$613 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. AbbVie, Inc. $3,009 181 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $1,374 72 payments
  3. Janssen Biotech, Inc. $1,235 46 payments
  4. Celgene Corporation $664 52 payments
  5. Pfizer Inc. $524 25 payments
  6. E.R. Squibb & Sons, L.L.C. $459 5 payments
  7. Madrigal Pharmaceuticals $444 15 payments
  8. Genzyme Corporation $399 19 payments
  9. Ardelyx, Inc. $361 14 payments
  10. Regeneron Healthcare Solutions, Inc. $348 20 payments
  11. Other $2,354 103 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $11,076 547 payments
  2. Education $96 5 payments
Products named General payments · program years 2022–2025
  1. RINVOQ $1,539 88 payments
  2. ENTYVIO $1,273 66 payments
  3. ZEPOSIA $1,105 56 payments
  4. TREMFYA $922 31 payments
  5. SKYRIZI Immunology $791 42 payments
  6. CREON $760 50 payments
  7. SKYRIZI Immunology $663 46 payments
  8. LINZESS $556 42 payments
  9. XIFAXAN $486 23 payments
  10. STELARA $439 16 payments
  11. Other $4,561 216 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

334

Median for Physician Assistant: 241

Drug cost

$204,107

Median for Physician Assistant: $4,110

Branded share of claims

37.1%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 14 $95,039
Creon Lipase/Protease/Amylase Brand 30 $73,086
Linzess Linaclotide Brand 14 $18,999
Dexlansoprazole Dr Dexlansoprazole Brand 21 $7,110
Mesalamine Generic 19 $4,551
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 26 $1,696
Pantoprazole Sodium Generic 89 $1,164
Cholestyramine Cholestyramine (With Sugar) Brand 19 $794
Esomeprazole Magnesium Generic 21 $628
Omeprazole Generic 43 $500

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 8 billing codes

Paid by Medicare

$22,110

Medicare's payments for the services billed

Medicare patients

263

Average age 74

Services billed

282

162 women, 101 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 63%
Arthritis 52%
Ischemic heart disease 31%
Diabetes 23%
Osteoporosis 21%
Chronic kidney disease 19%
Cancer 16%
Depression 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $369
$369 — —
STELARA
  • Janssen Biotech, Inc. $362
$362 — —
TREMFYA
  • Janssen Biotech, Inc. $223
$223 — —
RINVOQ
  • AbbVie, Inc. $207
$207 — —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $144
  • GENZYME CORPORATION $58
$202 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

552 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record